Dyslipidemi

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

PRALUENT^®: a PCSK9i that ticks all the boxes^1–4

PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.² It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.² Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.¹

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens

Nu har du som arbetar med sekundärprevention möjlighet att djupdyka inom det ämne som intresserar just dig. Se inspelningar från webbinarier, presentationerna hålls av medicinska experter.